How do you approach CNS prophylaxis in patients with DLBCL?
Would you follow an algorithm such as the one proposed by Hall et al?
How do you decide between intrathecal chemotherapy vs systemic therapy with HD-MTX?
Answer from: Radiation Oncologist at Community Practice
I think the NCCN-CNS-IPI based on the German data is a reasonable place to start when it comes to making decisions regarding CNS prophylaxis. We typically do IT MTX for patients on the lower end of the risk spectrum and high dose IV MTX for patients on the higher end of the risk spectrum
Sign in or Register to read more